SF3B1 and prostate carcinoma: Furthermore, mutations in SF3B1 have been reported at low frequencies in patients with acute myeloid leukemia, breast cancer, prolactinomas, uveal melanoma, leptomeningeal melanoma, blue nevus-like cutaneous melanoma, pancreatic ductal adenocarcinoma, and prostate cancer [151–159].